Grail, Inc. (NASDAQ:GRAL) CEO Robert P. Ragusa Sells 7,625 Shares

Grail, Inc. (NASDAQ:GRALGet Free Report) CEO Robert P. Ragusa sold 7,625 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $31.21, for a total value of $237,976.25. Following the completion of the sale, the chief executive officer now owns 828,662 shares in the company, valued at $25,862,541.02. This represents a 0.91 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Grail Trading Up 1.0 %

Shares of NASDAQ GRAL opened at $30.85 on Thursday. Grail, Inc. has a 1-year low of $12.33 and a 1-year high of $63.99. The business’s 50 day moving average is $31.42 and its 200-day moving average is $21.15.

Grail (NASDAQ:GRALGet Free Report) last announced its earnings results on Thursday, February 20th. The company reported ($1.86) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.41) by $2.55. The firm had revenue of $38.25 million for the quarter, compared to the consensus estimate of $35.33 million. On average, sell-side analysts forecast that Grail, Inc. will post -15.15 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Grail

A number of large investors have recently made changes to their positions in the company. Crcm LP bought a new position in Grail during the 4th quarter worth $65,061,000. Sessa Capital IM L.P. bought a new position in Grail during the 4th quarter worth $53,550,000. Primecap Management Co. CA bought a new position in Grail during the 4th quarter worth $37,118,000. Baker BROS. Advisors LP bought a new position in Grail during the 4th quarter worth $29,098,000. Finally, Vanguard Group Inc. bought a new position in Grail during the 4th quarter worth $25,902,000.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Wolfe Research assumed coverage on Grail in a research note on Friday, November 15th. They issued a “peer perform” rating on the stock. Morgan Stanley began coverage on Grail in a research note on Wednesday, November 27th. They issued an “equal weight” rating and a $16.00 price objective on the stock.

Check Out Our Latest Analysis on GRAL

About Grail

(Get Free Report)

GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.

See Also

Insider Buying and Selling by Quarter for Grail (NASDAQ:GRAL)

Receive News & Ratings for Grail Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grail and related companies with MarketBeat.com's FREE daily email newsletter.